Evidence map›Paper›PMID 27488909›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2017

Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults.

Siobhan M Hoscheidt, J Mikhail Kellawan, Sara E Berman, Leonardo A Rivera-Rivera, Rachel A Krause, Jennifer M Oh, Michal S Beeri, Howard A Rowley, Oliver Wieben, Cynthia M Carlsson and 4 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06072963 (Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06072963 phase2recruitingstarted 2024, after this paper: background citation

Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study

Ran2024Enrolled80Registered outcomes15Posted comparisons0ConditionsAlzheimer Disease, Metabolic Syndrome, Mild Cognitive ImpairmentArmsIntranasal insulin, Intranasal insulin placebo, semaglutide, Semaglutide placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Metabolic Syndrome and Dementia Risk in Older Adults: A Narrative Review.The Kaohsiung journal of medical sciences · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Sex differences in gray matter, white matter, and regional brain perfusion in young, healthy adults.American journal of physiology. Heart and circulatory physiology · 2024
    Article
  16. Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy.International journal of molecular sciences · 2024
    Review
  17. Article
  18. Article
  19. The Metabolic Syndrome, a Human Disease.International journal of molecular sciences · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Siobhan M Hoscheidt1 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
J Mikhail Kellawan2 Department of Kinesiology, University of Wisconsin, Madison, WI, USA.
Sara E Berman1 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Leonardo A Rivera-Rivera3 Department of Medical Physics, University of Wisconsin, Madison, WI, USA.
Rachel A Krause1 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Jennifer M Oh1 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Michal S Beeri5 The Joseph Sagol Neuroscience Center, Sheba Medical Center, Israel.
Howard A Rowley1 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Oliver Wieben3 Department of Medical Physics, University of Wisconsin, Madison, WI, USA.
Cynthia M Carlsson1 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Sanjay Asthana1 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Sterling C Johnson1 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
William G Schrage2 Department of Kinesiology, University of Wisconsin, Madison, WI, USA.
Barbara B Bendlin1 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
University of Wisconsin–Madison · USGeriatric Research Education and Clinical Center · USSheba Medical Center · IL

Funding

Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI JOHNSON, JEFFREY A · 2009 to 2018
$16.2M
INTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3M
Inflammation, long-term diabetes characteristics, and cognitive declineR01AG034087 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHNAIDER BEERI, MICHAL · 2009 to 2014
$3.7M
Two Diseases or one? The early pathogenesis of vascular mediated cognitive decline and Alzheimer's Disease.F30AG054115 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BERMAN, SARA ELIZABETH · 2016 to 2019
$166k
NIA NIH HHS F30 AG054115NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG034087NIGMS NIH HHS T32 GM008692
6 · The paper itself

Abstract

Insulin resistance (IR) is associated with poor cerebrovascular health and increased risk for dementia. Little is known about the unique effect of IR on both micro- and macrovascular flow particularly in midlife when interventions against dementia may be most effective. We examined the effect of IR as indexed by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) on cerebral blood flow in macro- and microvessels utilizing magnetic resonance imaging (MRI) among cognitively asymptomatic middle-aged individuals. We hypothesized that higher HOMA-IR would be associated with reduced flow in macrovessels and lower cortical perfusion. One hundred and twenty cognitively asymptomatic middle-aged adults (57 ± 5 yrs) underwent fasting blood draw, phase contrast-vastly undersampled isotropic projection reconstruction (PC VIPR) MRI, and arterial spin labeling (ASL) perfusion. Higher HOMA-IR was associated with lower arterial blood flow, particularly within the internal carotid arteries (ICAs), and lower cerebral perfusion in several brain regions including frontal and temporal lobe regions. Higher blood flow in bilateral ICAs predicted greater cortical perfusion in individuals with lower HOMA-IR, a relationship not observed among those with higher HOMA-IR. Findings provide novel evidence for an uncoupling of macrovascular blood flow and microvascular perfusion among individuals with higher IR in midlife.

Indexed as

AgedBlood Flow VelocityCerebral ArteriesCerebrovascular CirculationCognitionContrast MediaDementiaFemaleHumansInsulin ResistanceMagnetic Resonance ImagingMaleMiddle AgedModels, BiologicalPerfusionContrast MediaAlzheimer’sarterial spin labelingcerebral blood flowcerebrovascular diseasediabetes

Identifiers

PMID27488909
PMCPMC5464714
OpenAlexW2503067938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.